CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers. - Wikidata - awgldk - TriplyDB

CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.

CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.

http://www.wikidata.org/entity/Q34360012

about

Maraviroc: a review of its use in HIV infection and beyond Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner.Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial.Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.Clinical relevance of CYP3A5 genotype on maraviroc exposures.Off-label use of maraviroc in clinical practice.Precision medicine for HIV: where are we?Genetic Variation of the Kinases that Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells.Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067.

P2860

Q26778504-E8FF450E-1E64-4524-92FA-9B9F465DAEF4 Q36106256-6978E070-64A2-4526-AFF3-5A83BBBC1501 Q37116845-8F62F18A-4978-4CF3-A402-B0BA161C2D04 Q39730219-1CA0B7C7-7CCF-4CDC-BD09-56A25C111C7E Q42592141-47D65B3C-645A-4632-B815-4B81726ABB4C Q42654565-154E623E-ADE3-47F2-BCD9-289C5E3940B4 Q47569821-53944933-D1E1-4935-9F4B-360B8012E07D Q49888809-9EBF96B4-3567-43F9-98E0-44C00C09E4E2 Q52594148-CFD5F6DE-AEFB-424D-8573-DD0BA0B04500

P2860

CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.

http://www.wikidata.org/entity/Q34360012

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.

@ast

CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.

@en

CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.

@nl

type

label

CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.

@ast

CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.

@en

CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.

@nl

prefLabel

CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.

@ast

CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.

@en

CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.

@nl

P1433

Q34360012-72E41F84-5E02-45E9-B8C4-DA220DC81192

P1476

Q34360012-B6158689-E23E-4154-8C1E-CE2EDFDFCF06

P2093

Q34360012-25161ED9-C0CC-4F70-944C-52C7CCD885EC

Q34360012-3BF60ABC-1A77-4312-AC1D-7177E37E8394

Q34360012-6D7F2A38-BDED-4B67-B94E-7E06E50DAC9C

Q34360012-774EBD34-AEBA-4D3E-8675-7D34D260CD8B

P2860

Q34360012-00763E07-E182-407B-91B5-C386533C53B3

Q34360012-05226177-482B-4A38-A4C7-C450983127C8

Q34360012-0B0B4827-C1E3-471E-B364-C798C3533456

Q34360012-15A7D291-D696-48BF-B464-2EDEB6EDAF89

Q34360012-28007D09-927F-4ECE-9DBE-7A644936F9DC

Q34360012-2A6680F9-3797-4090-BA5B-220D79FE066D

Q34360012-2C075243-63F2-4904-A579-61F90E2094A2

Q34360012-30E490DE-086D-459D-BD96-6ADAAD085F2E

Q34360012-313952CB-BEC5-4F65-87B5-D4F8BE623633

Q34360012-361E51FE-543D-4CA7-B208-1C56D7C207D2

P304

Q34360012-3E7A4FF5-1F8A-43B1-916A-726CDBF2695B

P31

Q34360012-4DFBDA11-1F21-4943-A96D-876DDDE820B3

P356

Q34360012-6DB8F2FB-94A4-4E76-A521-39CDCE566C97

P433

Q34360012-AE65BC68-FBFC-474B-95D7-3F6577501A73

P478

Q34360012-489A1AED-97DB-40AE-B587-30C232ABE8EA

P577

Q34360012-7732C330-1CBC-4250-ABA1-B9B2D17584BA

P5875

Q34360012-2B8FADB8-F649-4B22-A6FD-87FE20020AAB

P698

Q34360012-0C52A9BB-66AA-43BE-A1EE-6ECD82FBC0AA

P932

Q34360012-B85CE6FB-373F-4207-A82F-77E879D637B1

P356

P1433

Drug Metabolism and Disposition

P1476

CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.

@en

P2093

Craig W Hendrix

http://www.w3.org/2001/XMLSchema#string

Edward J Fuchs

http://www.w3.org/2001/XMLSchema#string

Namandjé N Bumpus

http://www.w3.org/2001/XMLSchema#string

Yanhui Lu

http://www.w3.org/2001/XMLSchema#string

P2860

Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects

Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue

Genetic contribution to variable human CYP3A-mediated metabolism

CYP3A gene expression in human gut epithelium

Maraviroc: pharmacokinetics and drug interactions

Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests

Genetic variability in CYP3A5 and its possible consequences.

A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function.

Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma.

Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir

P304

1796-1802

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/DMD.114.060194

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264796482

http://www.w3.org/2001/XMLSchema#string

P698

25117426

http://www.w3.org/2001/XMLSchema#string

P932

4201129

http://www.w3.org/2001/XMLSchema#string